Hutchison China MediTech Ltd ("Chi-Med")

Hutchison China MediTech Ltd ("Chi-Med"):
Focused on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. Chi-Med has a portfolio of 8 drugs in clinical development from own discovery engine in its Innovation platform and a cash generating Commercial platform with 2,500+ sales reps. Launched fruquintinib, partnered with Eil Lilly, in late stage colorectal cancer in China in November 2018. Global collaboration with AstraZeneca in two registration enabling studies with savolitinib in Tagrisso refractory lung cancer that is MET+ and EGFRm+ (global) and MET Exon 14 deletion NSCLC (China). Potential to start two registration programs globally in 2020.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Asia, US - Middle Atlantic
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Immunotherapy, Oncology
Finance
Profitable, Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Website:
Address:
230 Park Ave
10th Fl
New York, NY 10169
United States
10th Fl
New York, NY 10169
United States
More info:
My account:
Company Participants at Solebury Trout Management Access SF 2020
- Christian Hogg, CEO
- Mark Lee, SVP Corporate Finance and Development
- May Wang, SVP BD & Strategic Alliances
- Weiguo Su, PhD, EVP & CSO
Top 10 Holders of Hutchison China Meditech Ltd Sponsored ADR
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Capital International, Inc. | 3.49 | 4,805,189 | 164.00 | 13F | 9/30/20 |
Capital Research & Management Co. (International Investors) | 3.27 | 4,507,442 | 153.84 | 13F | 9/30/20 |
M&G Investment Management Ltd. | 2.47 | 3,400,816 | 116.07 | 13F | 9/30/20 |
Sands Capital Management LLC | 2.37 | 3,272,034 | 111.67 | 13F | 9/30/20 |
Wellington Management Co. LLP | 2.09 | 2,880,942 | 98.33 | 13F | 9/30/20 |
Zeal Asset Management Ltd. | 1.95 | 2,692,611 | 91.90 | 13F | 9/30/20 |
Capital Research & Management Co. (World Investors) | 1.65 | 2,271,707 | 77.53 | Funds | 12/31/20 |
Schroder Investment Management (Singapore) Ltd. | 1.37 | 1,891,819 | 64.57 | 13F | 9/30/20 |
Schroder Investment Management (Hong Kong) Ltd. | 1.24 | 1,713,179 | 58.47 | 13F | 9/30/20 |
BlackRock Fund Advisors | 1.23 | 1,693,781 | 57.81 | 13F | 9/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.